Teladoc Health Inc. (TDOC) shares plummeted 5.01% in pre-market trading on Thursday, as investors reacted to the company's disappointing first-quarter 2025 earnings report and subsequent analyst downgrades. The telehealth provider continues to face challenges in its core business segments, prompting concerns about its near-term growth prospects.
According to the Q1 2025 earnings call highlights, Teladoc reported consolidated revenue of $629.4 million, down 3% year-over-year. The company also posted a net loss of $0.53 per share, which included a noncash goodwill impairment charge of $0.34 per share pretax. The BetterHelp segment, in particular, experienced an 11% decline in revenue compared to the prior year, with adjusted EBITDA margin decreasing from 5.7% to 3.2%.
Following the earnings release, several analysts lowered their price targets for Teladoc stock. Leerink Partners cut its target price to $7.50 from $10.00, while Stifel reduced its target to $8 from $9. Canaccord, despite maintaining a Buy rating, lowered its price target to $12 from $14. These downgrades reflect growing concerns about Teladoc's ability to navigate the challenging telehealth landscape and return to profitable growth in the near term.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.